ArticleJournal of neuro-oncology2026
Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 - 005).
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe optimal adjuvant treatment strategy for spinal ependymomas (SEs) is controversial, especially in patients with adverse risk factors. The efficacy of adjuvant radiotherapy (RT) and its prognostic factors remain understudied.
methodsThis retrospective, multicenter study analyzed 45 adult patients (≥ 18 years) with histologically proven SE (WHO Grade 2 and 3) treated with RT between 1998 and 2024. Patients with Grade 1 tumors or surgery-to-RT intervals exceeding 6 months were excluded. Clinical outcomes were estimated using the Kaplan-Meier method, and prognostic factors were identified using multivariate Cox regression analysis.
resultsIn the Grade 2 cohort (n = 37; median follow-up: 7.9 years), gross total resection (GTR) was achieved in 43.2% of patients. Extent of resection served as the primary determinant of disease control: zero local failures occurred in the GTR group (100% 10-year local control (LC) and disease-free survival (DFS), whereas 41.2% of non-GTR patients experienced local failure (5- and 10-year DFS: 63.9% and 54.7%, respectively; p = 0.006). Despite superior local control with GTR, overall survival remained statistically similar between resection groups (10-year OS: 88.9% for GTR vs. 74.3% for non-GTR; p = 0.70). In non-GTR patients without initial dissemination, a surgery-to-RT interval exceeding 1.5 months was identified as the sole independent predictor of early recurrence (HR: 13.3 and 15.9 for DFS and PFS, p = 0.04 for both). Additionally, younger age and baseline spinal dissemination were independent adverse prognostic factors for progression and mortality. For Grade 3 tumors, the 5-year LC, progression-free survival, and OS rates were 56.3%, 41.7%, and 75.0%, respectively, with a 62.5% progression rate. Although GTR achieved complete LC in Grade 3 tumors, distant metastasis remained a primary pattern of failure, occurring in 60% of progressive cases. For patients with initial spinal dissemination, the progression rate was 60% with a median OS of 15.2 months.
conclusionWhile GTR remains the gold standard for long-term prognosis, adjuvant RT provides effective LC in Grade 2 SE patients with residual disease. Early adjuvant RT (within 1.5 months post-surgery) is a critical management strategy for non-GTR cases. Grade 3 histology and initial spinal dissemination remain significant indicators of poor long-term survival.
Indexed as
Identifiers
42726379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.